BioDelivery Sciences International (NSDQ:BDSI) said today that it reacquired the license to the Belbuca (buprenorphine) buccal film from Endo Pharmaceuticals. Malvern, Penn-based Endo Pharmaceuticals licensed the worldwide manufacturing and marketing rights to the opioid patch from BioDelivery in 2012.
Belbuca, a once-daily opioid, is indicated for the management of severe pain. The small, peppermint-flavored film works by sticking to the cheek and dissolving within 30 minutes. Projections show that Belbuca gross sales will exceed $27 million, according to Raleigh, N.C.-based BioDelivery.
“We respect Endo’s strategic decision regarding its U.S. branded pain portfolio and appreciate its role in bringing Belbuca to the market,” BioDelivery’s president & CEO Mark Sirgo said in prepared remarks. “While this change in direction is not what we originally envisioned for Belbuca, Endo has laid a significant foundation for Belbuca, and in so doing, has created a significant opportunity for BDSI. We recognize the hard work put forth by both companies since we entered our licensing and development agreement in 2012, and we appreciate the exceptional working relationship that has existed. We look forward to Endo’s support behind the upcoming transition.”
“We believe Belbuca is well positioned to provide healthcare providers and their patients a responsible solution for the treatment of chronic pain while also addressing the widespread concerns over the growing problem of opioid abuse, addiction and overdose in this country,” he added. “Belbuca provides important patient benefits and is well differentiated from other opioids. And as such, we believe Belbuca has promising growth potential and the ability to add tremendous value to our company.”
